Abstract Abundant preclinical and indirect clinical data have for several decades convincingly supported the notion that anti-angiogenesis is an effective strategy for the inhibition of tumor growth. The recent success achieved in patients with metastatic colon carcinoma using a neutralizing antibody directed against vascular endothelial growth factor (VEGF) has translated preclinical optimism into a clinical reality.With this transformation in the field of angiogenesis has come a need for reliable surrogate markers. A surrogate marker by definition serves as a substitute for the underlying process in question, and in the case of angiogenesis, microvessel density (usually in so-called ''hot-spots'') has until now been the most widely used parameter. However, this parameter is more akin to a static ''snap-shot'' and does not lend itself either to the dynamic in situ assessment of the status of the tumor microvasculature or to the molecular factors that regulate its growth and involution. This has led to an acute need for developing circulating and imaging markers of angiogenesis that can be monitored in vivo at repeated intervals in large number of patients with a variety of tumors in a non-invasive manner. Such markers of angiogenesis are the subject of this review.
Introduction
A comprehensive understanding of the molecular mechanisms that regulate angiogenesis has resulted in the design of new and more effective therapeutic strategies. Over the past few decades, a large number of angiogenesis inhibitors have been identified [1] many of which are currently being tested in clinical trials [2, 3] . For example, a vascular endothelial growth factor (VEGF)-specific neutralizing antibody bevacizumab (Avastin) has been added to conventional therapy for colon, rectal, lung, and breast cancer patients [4, 5] as have kinase inhibitors, sunitinib malate (Sutent) and sorafenib (Nexavar) [5] . However, there is at present no reliable means to monitor the effects of such regimens on the angiogenic process per se. It has therefore become imperative to identify surrogate markers for angiogenesis for the following reasons:
1. To direct the dosing and scheduling of an antiangiogenic therapeutic agent based on parameters (markers) that indicate maximal effect and minimal toxicity, rather than on maximum tolerated dose. 2. To define the optimal biological dosage of antiangiogenic drugs. 3. To provide an early measurable sign of tumor relapse/ recurrence.
4. To stratify patients according to their needs/regimens. 5. To define the best combinatory drug regime (i.e., antiangiogenic drug plus chemo-or radio-therapy). 6. To facilitate preliminary testing of potential new therapeutic agents
It has also been pointed out that the elimination of an entire tumor vascular network could reduce the efficacy of pharmacotherapy by preventing the access of cytotoxic drugs to the tumor cells [6] . Thus the aim of an optimal anti-angiogenic regimen could be to ''normalize'' the structure and function of tumor vessels to allow maximal delivery of cytotoxic drugs [7] , while at the same time preventing further angiogenesis. The identification, and above all, the validation of surrogate markers will help to achieve this objective. ''Classical'' tumor markers include alpha-fetoprotein (AFP) for hepatocellular carcinoma and germ cell tumors, carcinoembryonic antigen (CEA) for gastrointestinal tumors, lung cancers and some breast cancers, prostate specific antigen (PSA) for benign and malignant prostate cancer, human chorionic gonadotropin (HCG) for trophoblastic tumors, calcitonin for medullary carcinoma of the thyroid, acidic prostatic phosphatases for metastatic bone disease, lactate-dehydrogenase (LDH) for lymphoma, testis cancer and pulmonary metastases, neuron specific enolase (NSE) for small cell lung cancer, and various specific tumor antigens, e.g., Ca-15.3 (adenocarcinoma of the breast, ovary and lung) and Ca-125 (ovarian carcinoma). These markers are tumor-specific and may have a place in measuring the efficacy of anti-angiogenic therapy. However, they are not surrogate markers of angiogenesis itself, and would thus have limited value in assessing specific inhibitory effects of this process.
To date, assessment of tumor vascularity has relied principally on counting the number of immunohistochemically identifiable microvessels in vascular hot spots in tumors [8] i.e., determining microvessel density (MVD). However, it has been demonstrated that changes in vessel diameter and MVD vary with tumor type and stage [9] . Also, Maniotis et al. [10] have demonstrated a novel process by which tumors may develop a well-structured microcirculation, which does not include the participation of endothelial cells and is independent of angiogenesis, the so-called ''vasculogenic mimicry''. In such cases, the common approach of staining endothelial cells for assessing the MVD would not provide an adequate indication of angiogenesis. Although the prognostic importance of MVD in breast cancer has been well established with results indicating a correlation between areas of most intense neovascularization and metastasis [11] , studies in other cancers have found no, or sometimes even negative correlations between MVD and metastasis [12, 13] .
Additionally, research has shown that the metabolic needs of cancer cells vary with the tissue of origin and change with tumor progression [14] . Thus, the number of tumor cells that can be supported by a vessel varies, and this in turn influences the vascular density of the tumor. Despite their often considerable angiogenic activity, certain human tumors can exhibit lower microvessel densities than the corresponding normal tissues [15] . Also, MVD following anti-angiogenic therapy is determined by the time-dependent ratio of capillary to tumor cell dropout, which in turn could result in increased, decreased or unchanged values of MVD [16] . Given these results, it is questionable whether MVD is the most appropriate method by which angiogenesis should be calibrated, particularly once therapy has been commenced. All of this points to the fact that noninvasive methods of evaluation may be more appropriate for the management and planning of anti-angiogenic therapy. Another source of inconsistency has been the differences in methodology for assessing MVD, i.e., different counting techniques, selection of microvessels, etc. [17] . Finally, it is not clinically feasible to regularly obtain MVD samples invasively from the patient throughout his/ her treatment. Since the MVD technique relies on the availability of tissue specimens, it cannot be used for repeated measurements of the dynamic processes of vessel growth and involution in vivo [18] .
Another commonly employed surrogate for angiogenesis and anti-angiogenic therapy is tumor volume. However, tumor volume changes are not consistent markers of angiogenic changes, with one study showing that the overt inhibition of angiogenesis in two human tumors was detectable before measurable effects on the tumor volume, while in another, although the tumor was responding well to treatment, its volume continued to increase [19, 20] . Finally, anti-angiogenic therapy might not necessarily result in tumor regression but might stabilize the tumor or return it to a dormant state.
The use of circulating and imaging markers of angiogenesis overcomes many of the limitations associated with the measurement of MVD and tumor volume and seems more amenable to characterizing angiogenesis in cancer patients. Circulating markers can either be soluble or cellular in nature, and can be measured at any stage of treatment. The assessment of circulating concentrations of angiogenic factors such as VEGF (vascular endothelial growth factor), an important mediator of normal and tumoral angiogenesis, in conjunction with the promising preclinical results obtained by blocking VEGF or its receptors, indicates that it may be a leading candidate in the hierarchy of circulating angiogenic markers [5] . Circulating blood platelets contain many factors with the potential to be angiogenic markers including VEGFs and other cytokines. Although plasma could provide an accurate indication of circulating levels of such markers, release of endogenous VEGF from platelets needs to be prevented to avoid false positives. Rapid progress in proteomic and genomic technologies also promises to redefine this field. In vivo vascular imaging provides quantitative assessments of vessel density and blood volume fraction, and is even able to measure blood flow, oxygenation, metabolic activity and vascular permeability [21, 22] . Current research is not only aimed at improving the resolution of these in vivo techniques, since their capacity to resolve individual microvessels (including angiogenic vessels) is limited, but also at expanding their ability to assess other functional parameters related to angiogenesis [23] .
Circulating markers of angiogenesis
The potential for soluble circulating protein markers to provide an indirect measure of tumor angiogenesis has been investigated in some detail. Soluble circulating molecules have been used as prognostic as well as surrogate markers.
Angiogenic growth factors and their receptors
Both VEGF and fibroblast growth factor-2 (FGF-2) play key roles in tumor angiogenesis [24] . They are produced by tumor as well as stromal cells, and hypoxia is a potent stimulator of VEGF transcription mediated by HIF-1a [25] . These growth factors are often sequestered in the extracellular matrix, and are liberated by extracellular proteolytic activity in the tumor microenvironment. Moreover, since their biological effects are dependent on binding to, activation of, and internalization by cell surface (tyrosine kinase) receptors, only growth factors capable of being receptor bound are of biological relevance [26] . In fact, total immunoreactive VEGF within node-negative breast tumors may have little value as a prognostic marker [27, 28] . Circulating levels of many angiogenic factors therefore depend on a variety of factors, including perfusion, protease activity and the hypoxic status of the tumor. To date, no clear correlation has emerged between circulating and receptor bound levels of VEGF and other angiogenic factors.
A large number of studies have demonstrated a strong association between elevated expression of VEGF by primary tumors and advanced disease or poor prognosis (including lymph node metastasis) in a variety of cancers [18, [29] [30] [31] . Protein and mRNA have been measured in tumor samples, and protein has also been measured in the circulation. Circulating VEGF is generally predictive of tumor status and prognosis (e.g., see [32] ), although there are important exceptions. Circulating VEGF has also been used to monitor the response to anticancer therapies and in follow-up surveillance for tumor relapse [29] . However, the data are generally tumor-and stage-specific (i.e., the findings cannot be applied across a wide spectrum of tumors), and there is a large degree of variability between studies on the same tumor type. The routine clinical use of plasma VEGF as a diagnostic, prognostic or surrogate marker has not yet been accepted.
There are reports supporting the prognostic value of other circulating angiogenic factors such as FGF-2, hepatocyte growth factor, platelet-derived endothelial cell growth factor, transforming growth factor-beta and angiogenin, but their clinical significance is less conclusive because of limited data [18, 29, 33] .
Soluble VEGFR-1 may serve as a biomarker for angiogenesis-associated diseases including cancer. For example, it has been detected in sera from patients with colorectal and breast cancer, but not in healthy individuals [34] . Recently, the identification of a soluble form of VEGFR-2 has been reported [35] . Whether it may serve as a biomarker for angiogenesis remains to be determined.
VEGF and its receptors are clearly prime candidates in anti-cancer therapies targeting angiogenesis. A recent study has demonstrated that circulating plasma VEGF is increased in both normal and human tumor-bearing mice following therapy with a blocking anti-VEGFR-2 antibody [36] . In the latter, both human and murine VEGF were increased. The mechanism may involve displacement of VEGF from VEGFR-2 by the antibody, although this remains to be demonstrated. However, VEGF was not elevated in mice treated with a soluble low-molecular weight VEGFR tyrosine kinase inhibitor. These studies demonstrate the potential of VEGF as a surrogate marker for receptor-blocking antibodies, and highlight the likelihood that because of unpredictable biological effects, each anti-angiogenic therapy will require specific markers.
Cell adhesion and extracellular matrix molecules A variety of soluble forms of other molecules involved in the angiogenic process, namely adhesion molecules, extracellular matrix (ECM) components, proteases and protease inhibitors, have been measured in the sera and plasma of cancer patients. These include but are not limited to E-selectin, vascular cell adhesion molecule-1 (VCAM-1), endoglin/CD105, thrombospondin (TSP) and matrix metalloproteinase (MMP)-9 [18, 37] . While the prognostic potential of some of these molecules has been reported, their use as surrogate markers still remains to be established. For example, serum VCAM-1 is closely correlated with microvessel density in breast cancer [38] , and higher levels were seen in women with lymph node-positive high grade than node-negative low grade tumors. As a second Angiogenesis (2008) 11:321-335 323 example, it was recently shown that low-dose metronomic chemotherapy increases plasma levels of the endogenous angiogenesis inhibitor TSP-1, in human tumor-bearing mice [39] .
Circulating endothelial cells and their precursors
Putative endothelial progenitor cells (EPCs) were first identified in peripheral blood by Asahara et al. in 1997 [40] . Although extensive work has gone into validating and extending these findings, controversy still exists as to the nature and role of these cells in the angiogenic process. The blood concentrations of circulating endothelial cells (CECs) and EPCs are elevated in cancer patients [41] and have been explored as biomarkers for the efficacy of antiangiogenic treatments of cancer [6, [42] [43] [44] [45] [46] . However, these populations are likely heterogeneous and may potentially be of different origin (e.g., shed by tumor endothelium or mobilized from the bone marrow) [42] . Thus, phenotypic characterization of these blood-circulating cells in cancer patients is warranted before their use as biomarkers. While serial analysis of gene expression in endothelial cells derived from blood vessels of normal and malignant colorectal tissues and in vitro characterization of endothelial cells expanded from human blood has established that CD146 is a reliable endothelial marker [47] [48] [49] [50] , other in vitro studies and more recent in vivo data have questioned its specificity for CECs [48, [51] [52] [53] . Whereas CD146 expression may become detectable on cultured endothelial cells in the setting of ex vivo colony formation assays [49] , it does not define bona fide endothelial or progenitor cells in primary blood samples from cancer patients. Characterizing the molecular profile of the putative EPC and specifically identifying determinants that distinguish it from CEC has been and remains a major challenge. Given this phenotypic variation for circulating versus tissue endothelial cells (Table 1 ) and the lack of specificity of CD146 expression, until a highly specific marker is discovered and validated, the quantitative evaluation of CECs or EPCs in the blood of cancer patients should be analyzed in conjunction with hematopoietic markers. Characterizing the phenotype of CECs and progenitor cell populations of interest as well as improving the analysis methodology are crucial for the clinical development and optimal use of such emerging biomarkers.
Alternative approaches for identifying novel angiogenic surrogates
In the approaches described thus far, classical knowledge of angiogenic factors has been translated into clinical assays. New technologies, including genomics and proteomics, are opening up novel analytical windows in the search for markers of angiogenesis. While classical technologies depend on the detection of pre-defined target molecules, the new technologies are more holistic, and may be able to identify surrogate patterns of gene, protein or metabolite expression indicative of an angiogenic state. For example, DNA levels are elevated in the circulation of cancer patients [54] [55] [56] [57] , and Swisher et al. (e.g. p. 53) [58] have shown that this DNA can bear tumor specific markers. The tumor vasculature regulates circulatory access to its microenvironment, and the functionality of this vasculature is determined by its angiogenic status, that may be modulated by anti-angiogenic therapies. Along these lines, quantitative PCR has been employed to estimate the levels of circulating DNA in patients with cancer [57] , which may exhibit potential as a surrogate for angiogenic status, although this has to date not been directly examined. Not only the quantity, but also the nature of free DNA might reflect the angiogenic status of a tumor, which may in future be amenable to analysis by DNA microarray technology.
Circulating leukocytes interact with and may be directly modulated by either the tumor microenvironment or via circulating cytokines and growth factors that accompany tumor progression. It is conceivable that the transcriptional activity of such modulated leukocytes may also exhibit potential as an angiogenic surrogate. Broad spectrum investigations of protein expression patterns (''proteomics'') have been employed to analyze the polypeptide content of plasma and serum in cancer patients at high resolution [59] [60] [61] [62] [63] [64] . Angiogenic responses in model systems have been demonstrated to generate novel circulating proteins [65] [66] [67] [68] . But, as has been noted elsewhere, the challenges associated with quantitation and validation of such approaches against the angiogenic status of each individual patient remain significant [69, 70] . The validation problem for nucleic acids is exacerbated because many of the necessary technologies depend on non-linear amplification of nucleic acid molecules. While these approaches are still in their infancy, such problems may eventually be resolved.
In addition to these methods, enhanced standard technologies may also be valuable for identifying angiogenic surrogates. One example is the Luminex technique, in principle a miniaturized ELISA, but one which allows the quantitation of hundreds of proteins in microlitres of body fluid [71] [72] [73] . In addition to quantifying levels of the usual suspects, VEGFs, FGFs, IL8, etc., expression signatures identified using computational techniques may yield novel surrogate markers of angiogenesis [74, 75] . As with most surrogates, validation in well defined pre-clinical models is indispensable, with subsequent substantiation within the clinical angiogenic context.
Imaging markers of angiogenesis
Since angiogenesis is a dynamic process, a technique for probing neovascularization in vivo without perturbing the tumor or its microenvironment would be highly appropriate for investigating the spatio-temporal relationships that exist between angiogenesis, tumor growth and metastasis. Any such non-invasive methods for monitoring the angiogenic status of solid tumors would be useful in the clinic for monitoring the efficacy of anti-angiogenic or anti-vascular therapies, for assessing the effects of hormonal therapy on vascularization or for determining the clinical grade of the lesion. A wide array of non-invasive imaging modalities have been used to image angiogenesis. These include X-ray computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), single-photon emission computed tomography (SPECT), ultrasound, and near-infrared optical imaging, each with its own distinct potential as a tool in the noninvasive, in vivo assessment of tumor angiogenesis. What follows is a brief description of applications of these modalities to assess angiogenesis, with MRI as the focal point.
Magnetic resonance imaging
The assortment of available MRI contrast mechanisms in conjunction with its exceptional dynamic functional range, make MRI highly efficacious for assessing tumor angiogenesis in vivo. There are two broad classes of contrast mechanisms that can be employed for imaging tumor angiogenesis with MRI: endogenous and exogenous (Fig. 1) . Endogenous or intrinsic contrast mechanisms are those in which the contrast arises from a naturally occurring substance in the body that has sufficient magnetic susceptibility to influence the MR signal, e.g., deoxyhemoglobin. Probing the tumor vasculature using the ''endogenous contrast agent'' deoxyhemoglobin present in the tumor microvessels is based on the blood oxygenation level dependent or BOLD contrast mechanism first described by Ogawa et al. [76] . The concentration of paramagnetic deoxyhemoglobin is the primary determinant of the eventual image contrast observed. The presence of deoxyhemoglobin in a blood vessel produces a difference in magnetic susceptibility between the vessel and the surrounding tissue. Such susceptibility differences induce heterogeneities in the magnetic field, on a microscopic scale, that induce dephasing of the MRI signal, leading to a reduction in the value of T2*. In a T2*-weighted imaging experiment, the presence of deoxyhemoglobin in the blood vessels will produce negative contrast, i.e., darkening in voxels containing vessels. Since oxyhemoglobin is diamagnetic and does not produce the same dephasing as does deoxyhemoglobin, changes in the oxygenation status of the blood can be observed as signal changes in T2*-weighted images. Such an approach was used to detect changes in tumor oxygenation and hence vascularization following induction of angiogenesis by angiogenic agents [77] and for obtaining maps of the ''functional'' vasculature in models using genetically modified animals [78] . While mainly dependent on the concentration of deoxyhemoglobin in the blood, other physiological parameters such as hematocrit, oxygen saturation, blood flow, blood volume, vessel orientation and geometry [79, 80] can all affect BOLD contrast. Yet another endogenous contrast MRI technique known as arterial spin labeling (ASL) was recently used to map the blood flow in tumors [81] . In this approach, water protons in the arterial blood pool serve as a perfusion indicator and initial studies in animal tumor models strongly supported the use of ASL as a valid approach for monitoring the effects of agents designed to change tumor perfusion. More recently, in a preliminary patient study, the use of ASL in conjunction with dynamic susceptibility-based contrast MRI for measuring relative regional cerebral blood flow changes in brain metastases after stereotactic radiosurgery was found to be predictive of treatment outcome [82] .
Endogenous contrast MRI has the advantage of being completely non-invasive, i.e., the measurement can be conducted repeatedly in the same patient without requiring any invasive procedure including the injection of contrast agent. However, while being capable of providing maps of relative changes in various physiological parameters with good spatio-temporal resolution, endogenous contrast methods do not provide absolute quantitative measures of angiogenic parameters such as the vascular-volume-fraction of the tumor, or vascular permeability. This implies that one must therefore resort to exogenous contrast MRI techniques for quantitation.
Exogenous or extrinsic contrast mechanisms arise from agents that alter the local magnetic field in the tissue of interest when administered to the subject, thereby enhancing the contrast in MRI. Unlike the radiolabeled tracers or chemical agents used in nuclear medicine or X-ray CT that are visualized directly on the image, MR contrast agents are visualized indirectly due to the changes they induce in water proton relaxation. The most commonly employed MR contrast agents are paramagnetic gadolinium (Gd) chelates [83] . The seven unpaired electrons of gadolinium produce large magnetic moments that shorten both the spin-lattice relaxation time (T 1 ) and spinspin relaxation time (T 2 ) of tissue water. On a T 1 -weighted MRI, tissues that take up the contrast agent are positively enhanced or brightened, while the observed contrast is reversed on T 2 -or T 2 *-weighted scans. Tracer kinetic principles are then employed to calculate the tissue concentration of the contrast agent from the MR signal intensity. The various Gd complexes in use can broadly be classified as either being low molecular weight (MW & 0.57 kDa) agents, or macromolecular (MW & 65 kDa) agents such as albumin-(Gd-DTPA) compounds that reside in the intravascular space for several hours.
The low MW agents are the only MR contrast agents approved for routine clinical use by the FDA. Such agents have been used to image a wide array of tumors ranging from brain to uterine tumors. However, in addition to tumor delineation, several functional or angiogenesis-relevant parameters can also be determined using these agents. However, these ''T 1 -weighted'' contrast methods involve the analyses of contrast agent-induced relaxivity changes to determine compartmental transfer constants as well as the extracellular extravascular volume fraction based on one of several theoretical compartmental models [84] . These approaches have resulted in the derivation of a wide range of clinically relevant angiogenesis-related parameters (see [22] for a detailed review). T 2 -and T 2* -weighted methods that rely on the susceptibility effect of these contrast agents have also been employed in the study of tumor angiogenesis. In addition to the traditional tumor blood volume measurements by both T 1 [85] and T 2 [86] , techniques that measure tumor vessel caliber [87, 88] , act as surrogates of tumor grade [89, 90] (Fig. 2) , predict delivery of chemotherapeutic agents to the tumor interstitium [91] , and aid in assessment of the efficacy of antiangiogenic therapies [92] (Fig. 3) have been added to the accouterment of available probes. Development of techniques for correcting the effects of contrast agent extravasation via the hyper-permeable tumor vasculature [86] , and the development of stereologic validation techniques for MRI approaches [93] , may herald a more widespread use of MRI in the clinical assessment and management of tumor angiogenesis. The availability of high MW contrast agents with long blood half-life times such as Albumin-Gd-DTPA complexes or polylysine-Gd-DTPA and gadomer-17, enable the quantification of parameters such as the tumor's vascular volume and the permeability surface area (PS) product while circumventing the primary disadvantage of low MW agents, namely their rapid extravasations from leaky tumor vessels. Under the assumption of water being in the fast exchange regime between all the tumor compartments, the concentration of the high MW contrast agent within a voxel is proportional to the changes in relaxation rate (1/T 1 ) before and after administration of the contrast agent. Relaxation rates can then be computed directly using either dynamic [94] , or steady-state T 1 MRI [95] and spatial maps of tumor vascular volume and PS constructed after fitting to the appropriate kinetic model. Assuming negligible reflux of the contrast agent and constant blood concentrations of the agent for the duration of the MR experiment, the contrast agent uptake within the tissue of interest can be modeled as a linear function of time. In this case, the slope of the concentration-time curve is proportional to the PS and the y-intercept, the vascular volume [96] .
Quantification of each of these parameters requires normalization to changes in relaxation rate of the blood, which can be obtained separately from blood samples taken before administration of the contrast agent and again at the end of the MR experiment. The various models of contrast agent uptake are reviewed in [84] . Finally, it should be kept in mind that the accuracy of tissue vascular volume measurements depends not only on factors such as compartmentalization of the contrast agent and the rate of water exchange between the vascular and extracellular compartments [97] , but also on factors such as the inflow of unsaturated spins and the type of imaging technique employed [98] . The use of high MW contrast agents has been successfully employed to assess the efficacy of anti-angiogenic therapy [99, 100] and to characterize differences in angiogenesis between metastatic and nonmetastatic breast and prostrate cancer xenografts as well as to study the role of the functional tumor vasculature in metastasis [101] .
Molecular MR imaging of tumor angiogenesis
While exogenous contrast agents enable us to probe various angiogenesis-related parameters and improve the contrast to noise ratio when performing MRI, the visualization of key receptors and molecular pathways fundamental to angiogenesis using MRI was not possible until very recently. This was primarily due to the low sensitivity of MRI compared to modalities such as PET and optical imaging for imaging pico-or nano-molar target concentrations, and other factors such as contrast agent delivery to the molecular target as well as dilution of the label within the blood pool. However, the design of novel strategies for receptor target amplification finally circumvented some of these issues making molecular MR imaging of sparse biomarkers at nanomolar or even picomolar concentrations possible [22] . These targeted contrast agents have included the use of conjugates of low molecular weight Gd-DTPA, protein carriers, dendrimers, iron oxide nanoparticles and liposomes [102] . An example of a high-relaxivity targeted contrast agent for molecular MRI of tumor angiogenesis is liquid perfluorocarbon nanoparticle emulsions that can carry several gadolinium atoms per particle [103] . An additional advantage of these perfluorocarbon constructs is that they are highly flexible and can be used as multimodal contrast agents [104] . Other novel studies have ranged from imaging inducible E-Selectin expression in human endothelial cell culture using cross-linked iron oxide nanoparticles (CLIO) covalently bound to high-affinity anti-human E-selectin F(ab 0 ) fragments [105] , to the detection of tumor angiogenesis in vivo by integrin a V b 3 -targeted MRI, in which the targeted MR contrast agent was composed of Gdlabeled polymerized liposomes conjugated with biotinylated antibodies targeted against the a V b 3 integrin, that is commonly found on tumor endothelial cell surfaces [106] . Although originally developed for applications such as measuring ICAM-1 expression in autoimmune encephalitis [107] , or for imaging fibrin-rich clots in an animal model of human thrombus formation [108] , these novel molecular imaging approaches could be extended or adapted to image the same or similar targets in an ''angiogenic'' milieu. The use of targeted contrast agents in conjunction with the functional imaging techniques described earlier has begun to provide unique opportunities for understanding receptor-mediated pathways in tumor angiogenesis using MRI.
Imaging tumor angiogenesis with complementary imaging modalities
In addition to MRI, several techniques for imaging tumor angiogenesis have been developed using other imaging modalities ( [109] reviews some of these). Both PET and SPECT imaging are quantitative techniques that are sensitive to very low concentrations of tracer molecules. PET, which is capable of detecting picomolar concentrations of tracer, is *ten times more sensitive than SPECT. Both methods are well suited to molecular imaging because of the generally low concentrations of target molecules, as well as for gathering hemodynamic data. However, because the radionuclides used in PET tracers have a very short half-life (2 min for 15 O, 10 min for 13 N, 20 min for 11 C, and 110 min for 18 F), PET studies are usually performed at facilities with a PET scanner and the necessary cyclotron and chemical synthesis laboratory for the preparation of such tracers. Radionuclides used for SPECT are easier to prepare and somewhat longer lived than those used for PET (6 h for 99m Tc, 67 h for 111 In, and 13.2 h for 123 I), with SPECT imaging being more widely available than PET imaging. However, both PET and SPECT images suffer from low spatial resolution compared to MRI or CT images. An innovative study using SPECT recently demonstrated the viability of imaging an antibody fragment against the ED-B splice variant of fibronectin, an angiogenic marker [110] . With this technique, the authors could distinguish between inactive and actively growing lesions in patients with lung, colorectal, or brain cancer. Advances in ultrasound imaging instrumentation and ultrasound blood-pool contrast agents have enabled the sonographic detection of tumor angiogenesis. A novel study using microbubbles targeted to a V integrins expressed in neovessels, enabled the non-invasive assessment of angiogenesis in vivo by ultrasound [111] . More recently, the quantification of tumor vascularity was achieved using a multi-modal approach [112] . In this study, the authors employed another microbubble contrast agent and contrast enhanced sonography to quantify tumor vascularization in mice using fractal analysis. Ultrasound measurements were compared with fractional vascular volume measurements using MRI and with fluorodeoxyglucose (FDG) PET measurements, to identify the viable regions within the tumor. An excellent correlation was found between ultrasound and MRI, as well as between the ultrasound and FDG PET measurements. The high sensitivity of photon detection, widespread availability of a large range of novel fluorescent probes and targets, and the development of near-infrared techniques has made optical imaging a favored modality for imaging molecular targets. More recently, diffuse near-infrared optical spectroscopy was employed to quantify the dynamics of optical contrast agents in a rat tumor model in vivo, in conjunction with MRI [113] . The kinetics of the optical contrast agent indocyanine green and methylene blue were found to be analogous to those of a macromolecular and small-molecular-weight MR contrast agent, respectively.
Conventional and quantitative microscopy techniques ranging from fluorescence and electron microscopy to confocal and multiphoton microscopy have been extensively employed to probe the morphological and functional anomalies of angiogenic tumor vessels (see [21] for an excellent review of these and complementary imaging techniques for imaging angiogenesis). Of these, high-speed intravital multiphoton laser scanning microscopy has been used successfully to obtain structural and functional images of the microvasculature, lymphatics, and of leukocyte-endothelial interactions in animal tumor models at very-high resolution, while circumventing disadvantages such as limited imaging depth and phototoxicity usually associated with traditional fluorescence microscopy [114] . Finally a special variant of multiphoton laser scanning microscopy known as secondharmonic generation imaging was recently employed to dynamically assess the modulation of collagen content in tumors in vivo [115] . The intense second-harmonic generation (SHG)-nonabsorptive frequency doubling of the excitation laser line produced by endogenous protein structures, forms the basis of this novel imaging approach. This in turn enables one to obtain high-resolution threedimensional images of the tissue architecture using a laserscanning microscope [116] . In addition to the abovementioned novel imaging techniques, the development of multimodal contrast agents, i.e., contrast agents simultaneously observable with two or more imaging modalities, allows researchers to simultaneously exploit the strengths of each imaging modality. One such study developed a contrast agent based on albumin that was triply-labeled with biotin, a fluorescent tag, and Gd-DTPA, allowing optical, plasma mass spectrometry and MRI detection of the same agent [117] . The biotin tag allowed in vivo chasing of the contrast material from the blood by intravenous administration of avidin that caused the contrast agent to disappear from the blood vessels, while that which had extravasated prior to administration of avidin was not cleared. Thus, one can modulate the rate of clearance of the contrast material from the circulation while imaging it. Although nuclear medicine techniques such as SPECT and PET tend to be limited in their spatial resolution and require the administration of radioisotopes, and light scattering in soft tissues often limits the effective depth of optical techniques, the development of multimodal probes promises to circumvent these drawbacks, by allowing us to exploit the sensitivity of these techniques, while combining them with the advantages of MRI, such as higher spatial resolution. While intravital microscopy approaches provide very high imaging resolutions and have provided crucial insights into the pathophysiology of tumors [118] , such techniques are limited in terms of the tissue depth that can be probed and the range of available functional contrast mechanisms.
Also worth mentioning here is the burgeoning field of nanotechnology (i.e., devices or technologies with spatial dimensions of the order of 1-1,000 nm) and its emerging role in cancer detection and therapy. Broadly, nanotechnologies fall into two classes: the first includes the design and fabrication of ''nanovectors'' or ''nanocarriers'' for the targeted delivery of various anticancer therapeutics or contrast agents for imaging, while the second includes the precise patterning or fabrication of surfaces or devices (e.g., nanotubes and nanowires) at nanoscale resolutions (see the excellent review by Ferrari et al. [119] for details). Several investigators have used nanoparticulate contrast agents directed to a V b 3 -integrins to image angiogenesis in vivo using MRI [103, 106] . As summarized by Weissleder [120] , both derivatized and ''smart'' iron oxide nanoparticles have been employed to probe molecular pathways central to cancer with MRI and complementary imaging modalities such as optical and CT imaging. More recently, quantum dots have also been employed to image angiogenesis [121] and distinguish different aspects of the tumor micromilieu such as microvessels, from the ECM [122] .
While in vivo imaging methods such as MRI are unable to match the resolution of optical techniques, they nonetheless have a wide array of contrast mechanisms that are sensitive to the angiogenic status of a tumor and are not limited in their tissue penetration. The development of high-resolution in vivo techniques in conjunction with the design of novel imaging probes and target amplification strategies promises to herald a new era in imaging angiogenesis, by eliminating the resolution disparity and enhancing the assessment of angiogenic vessel architecture and functionality.
The studies described earlier attest to the validity and reliability of the various imaging techniques that have been used to determine vascular parameters. In fact, an elegant study by Batchelor et al. [123] using both in vivo MRI markers and circulating markers of brain tumor angiogenesis, recently demonstrated that the pan-VEGF receptor tyrosine kinase inhibitor AZD2171 normalized the tumor vasculature and alleviated edema in glioblastoma patients. While no single imaging modality is ideal in all circumstances; each has strengths and weaknesses with respect to its availability, sensitivity, ease of accurate and reproducible quantification, the regions of the body that can be imaged, the availability of compatible intravascular contrast agents, and contrast agent toxicity.
Alternative approaches for identifying novel imaging markers As described above, targeting contrast agents to blood vessels using probes that bind specifically to ''molecular zip codes'' is a burgeoning area of research [124] . Exploiting the molecular heterogeneity of the tumor vasculature to simultaneously design targeted contrast agents as well as therapeutic payloads directed at the most susceptible new angiogenic vessels, is an extremely attractive option. A novel technique that has mapped much of the diversity of receptors in human blood vessels is ''in vivo phage display'' [125] . In vivo phage display involves screening with huge random libraries of peptides displayed as recombinant molecules on the surface of bacteriophage, to identify molecular targets to which specific phage bind [124] . This approach has enabled targeting not only of normal blood vessels [126] but also angiogenic tumor vessels [127] , and more recently, the identification of tumor ''stage-specific'' molecular zip codes [128] . Although the physiological basis of this vascular heterogeneity is an ongoing area of investigation, phage library panning holds much promise in terms of the identification of novel markers for imaging angiogenesis dynamically and in vivo in the future.
It is worth pointing out that the retrieval and analysis of molecular components leading to the identification of novel targets necessitates robust bioinformatics systems and novel statistical tools for data mining. Peale et al. [75] have nicely summarized the evolution and contribution of gene profiling techniques over the past several decades to the study of angiogenesis and vascular development. These techniques now include sophisticated analyses with new software tools that, in conjunction with analysis of human genetic data and transgenic mouse models, have helped develop our understanding from the level of individual genes to that of entire regulatory networks [129] . In fact, the complexity of microarray data, its integration with multi-dimensional, multi-parametric imaging and/or other types of clinical data have heralded the new discipline of ''systems biology'', which provides a framework and methods for comprehending the interactions between these data [129, 130] . Novel multidimensional ''visualization'' and ''data-mining'' tools such the proposed ''connectivity map'' will empower researchers to avoid oversimplifications and appreciate the information contained in these complex interactions [131] . These same approaches could then be employed for the identification and development of heretofore unknown markers of tumor angiogenesis.
Conclusion
The demonstration that neutralizing anti-VEGF antibodies are efficacious in prolonging survival in metastatic colon cancer has given credence to the principle of mechanismdriven drug development [4] . This antibody has also been shown to have measurable therapeutic and biological effects in breast, renal and rectal carcinoma [45, 132, 133] . With regard to the latter, Willett et al. [45] have shown that following a single infusion of antibody, reductions are seen in tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of EPCs, while vessel maturity (pericyte coverage) was increased. This confirms the usefulness of histological, circulating and imaging markers in monitoring the effects of an antiangiogenic agent prior to the appearance of overt changes in tumor size.
As our understanding of the process of tumor blood vessel formation evolves, new markers will be identified that will be accurate measures of the angiogenic process. Exciting prospects include the use of gene arrays to provide an angiogenesis profile, from which appropriately validated markers could emerge. Biomarkers in turn could become targets for therapy as, e.g., an anti-HER2 monoclonal antibody (trastuzumab or Herceptin) and a BCR-ABL kinase inhibitor (imatinimb mesylate or Gleevec). In summary, recent clinical validation of a very large body of preclinical data points to the efficacy of anti-angiogenic therapy for the treatment of cancer. As the number of clinically validated anti-angiogenic agents increases, optimization of dose and schedule are likely to be based on levels of surrogate markers rather than on maximum tolerated dose, and this will be accompanied by a concomitant demand for non-invasive imaging techniques to assess the efficacy of such an approach in vivo.
